Sabiporide
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2000 (NCT02227030)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sodium/hydrogen exchangerINHIBITOR
NHE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1- Mol. weight
- 408.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105423 ↗
Also known as
- biib 722 cl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02268604 | Phase 1 | Oct 1, 2010 | Boehringer Ingelheim |
| NCT02224079 | Phase 1 | Apr 1, 2002 | Boehringer Ingelheim |
| NCT02227030 | Phase 1 | Apr 1, 2000 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 2000 |
1 organizations
Page 1 / 1